Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. - Wikidata - wikimedia - TriplyDB

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.

http://www.wikidata.org/entity/Q41338910

about

Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii Clinical and economic outcomes of Acinetobacter vis a vis non-Acinetobacter infections in an Indian teaching hospital.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.Understanding synergy.Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin.In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.Combating carbapenem-resistant Acinetobacter baumannii by an optimized imipenem plus tobramycin dosage regimen - prospective validation via hollow fiber infection and mathematical modeling.Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China.

P2860

Q28478890-591A81E5-B722-419E-BA23-E92B99CC54CF Q28485988-05582498-0114-4072-A9AC-4EBD375E20D9 Q35168882-5E6D76B9-9311-4DAD-B072-C901E3983B40 Q35168931-5C81C38E-83AD-4BBE-AF29-98873422E8FB Q36606740-4FD85E9B-BF76-4AFD-A0EE-404AB51F1B07 Q37660762-63B5934D-BD09-4891-B60D-C8D4D5F40B90 Q37869910-4A3342AC-B6FB-4832-B3DE-FC10B0F3AEAC Q38065010-9E82E6A4-A52E-4997-87C5-166CFF42B7C4 Q38652103-46F50113-1F8C-4AA5-BDFA-D3B655861B76 Q38749960-71429508-77AC-4203-8D51-2088F88C0570 Q41752271-FE90D4AC-6412-4D32-8DF2-8A49AB9F04A7 Q42186280-996F25EA-62FB-4501-A53F-03F12D2D966E Q46172822-9AA8EBB5-6043-450B-90F2-D853E71E40C2 Q47562492-80EB8857-8B50-406F-BDEB-038A15BE8BCA Q50872389-CEA14E66-1C61-49EC-8C00-E651FED10325

P2860

Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.

http://www.wikidata.org/entity/Q41338910

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Quantitative assessment of com ...... stant Acinetobacter baumannii.

@en

type

label

Quantitative assessment of com ...... stant Acinetobacter baumannii.

@en

prefLabel

Quantitative assessment of com ...... stant Acinetobacter baumannii.

@en

P1433

Q41338910-6B27D10C-4CDD-4E7F-A26F-8AE932F113AD

P1476

Q41338910-232432CF-AA46-4EBE-A3D4-E309F018C29D

P2093

Q41338910-050DCE48-231F-4A2B-A06C-F9EC016198C6

Q41338910-0E29DBC2-6656-41BB-83D2-5A1BA919BF66

Q41338910-585CF814-7342-4AE2-9AD9-9FEB0D21B1BB

Q41338910-8ECA0F8D-A896-43F2-9CBF-090BAF0914AD

Q41338910-923118AC-391B-4A8F-929E-3940AC2AEE42

Q41338910-98F04182-24CB-4E62-90A8-F96105E22D23

Q41338910-9D0986A2-FE85-4B97-A02C-E30AB74F3CBC

Q41338910-C9A2B7E1-4F21-4D7F-81BB-69C7229C9E55

Q41338910-DBDA54DD-0D1F-40BD-9E24-E439BAD3A625

P2860

Q41338910-0A8FC177-F6C1-4FCB-A9BC-D63CD73CA23F

Q41338910-12FEB965-9FBE-4427-9EE1-DD148DF20084

Q41338910-271F22C5-F629-4F7D-A554-C2D29729C9A5

Q41338910-3C6521B2-54A2-48D6-B2A1-87962510E3AB

Q41338910-4E411154-2921-435E-A143-8592E38CE22C

Q41338910-52D31936-6994-4521-817A-F68F4EC7179E

Q41338910-52D8E3AC-A52A-43BC-8BD7-70B651499EB7

Q41338910-5D202C18-2E1B-4783-B83F-8C2F2D2093C0

Q41338910-6C027253-FDDE-4FCA-8A99-067E68709B70

Q41338910-7E2FEA7B-8602-40F4-BE54-0C526A89F8DD

P304

Q41338910-9C236D48-06BE-47C3-A073-80650AEBAE87

P31

Q41338910-002E6F74-489E-4CDD-A415-78470CF4A03F

P356

Q41338910-79671BF1-4114-485F-88CE-51B85FA18F3F

P407

Q41338910-40F6534E-5746-4E37-B52E-C89970DD4287

P433

Q41338910-40B40FBB-63B4-4AFD-9F55-680FB9BD7C2D

P478

Q41338910-FAF5AA61-A646-4ECF-B1C1-2780A3546C4B

P577

Q41338910-E09B2BBB-7A91-4FF2-A1A6-985588441561

P5875

Q41338910-B71384B9-A192-49D1-B534-66EEEBE79A70

P698

Q41338910-3517B30D-93C2-4B8B-A753-3734065F31CA

P921

Q41338910-0C2EE83E-A8C8-4704-9915-3AF88DB1F605

Q41338910-81EDF379-CD27-455D-85C9-5E5E0BC3973A

P932

Q41338910-C060EB85-28AF-4410-8F83-E2764A200EB6

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Quantitative assessment of com ...... stant Acinetobacter baumannii.

@en

P2093

Andrea L Kwa

http://www.w3.org/2001/XMLSchema#string

Jing-Guo Hou

http://www.w3.org/2001/XMLSchema#string

John P Quinn

http://www.w3.org/2001/XMLSchema#string

Kai-Tai Chang

http://www.w3.org/2001/XMLSchema#string

Kimberly R Ledesma

http://www.w3.org/2001/XMLSchema#string

Michael Nikolaou

http://www.w3.org/2001/XMLSchema#string

Randall A Prince

http://www.w3.org/2001/XMLSchema#string

Tze-Peng Lim

http://www.w3.org/2001/XMLSchema#string

Vincent H Tam

http://www.w3.org/2001/XMLSchema#string

P2860

Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults

Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro

The triple combination indinavir-zidovudine-lamivudine is highly synergistic.

Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004.

Overview of nosocomial infections caused by gram-negative bacilli.

Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.

Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii.

P304

2898-2904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01309-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5344782

http://www.w3.org/2001/XMLSchema#string

P698

18505848

http://www.w3.org/2001/XMLSchema#string

P921

Acinetobacter baumannii

multiple drug resistance

P932

2493134

http://www.w3.org/2001/XMLSchema#string